Shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Zacks has also assigned Citius Pharmaceuticals an industry rank of 85 out of 256 based on the ratings given to its competitors.
An institutional investor recently raised its position in Citius Pharmaceuticals stock. Vanguard Group Inc. raised its position in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 453,156 shares of the company’s stock after acquiring an additional 342,180 shares during the quarter. Vanguard Group Inc. owned 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent quarter. 1.47% of the stock is currently owned by institutional investors and hedge funds.
CTXR traded up $0.01 on Wednesday, reaching $1.08. 9,900 shares of the company’s stock were exchanged, compared to its average volume of 153,525. Citius Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $2.52. The company’s 50 day moving average is $1.11 and its 200-day moving average is $1.15. The company has a market cap of $23.85 million, a price-to-earnings ratio of -0.92 and a beta of 0.55.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Read More: Coverage Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.